A role for DICAM+ mononuclear phagocytes in controlling neuroinflammation in multiple sclerosis

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS). In MS, CNS-infiltrating monocytes differentiate to tissue resident macrophages which are found in large numbers within the injured areas of the brain where they play a central role in driving disease progression through demyelination and tissue destruction. However, infiltrating monocytes and their derivative macrophages can also serve protective functions. In this study we investigated a possible role of intrathecal mononuclear phagocytes (infiltrating monocytes and macrophages) expressing dual immunoglobulin domain-containing cell adhesion molecule (DICAM) in neuroinflammation. Compared to symptomatic controls, treatment-naïve patients with relapsing-remitting MS had a reduced prevalence of DICAM + mononuclear phagocytes in CSF. When patients were treated with natalizumab, an antibody blocking migration of blood leukocytes to the CNS, we observed that DICAM + monocytes were still recruited to the CSF and that the level of soluble DICAM (sDICAM) in CSF was significantly increased compared to untreated patients. sDICAM and the prevalence of DICAM + mononuclear phagocytes in CSF furthermore correlated negatively with concentrations of various cytokines, including TNFa. Analysing the functional properties of DICAM showed that LPS-induced TNFa-production in mononuclear phagocytes was effectively reduced by signalling through surface-bound DICAM. This discovery, together with the observation of a high prevalence of infiltrating DICAM + mononuclear phagocytes in individuals with no disease or in which disease was kept under control, suggests an immunomodulatory role of DICAM + mononuclear phagocytes. Also, DICAM can engage in homophilic interaction with DICAM on other cells, suggesting that the increased intrathecal sDICAM of natalizumab-treated patients may help regulate inflammation in a paracrine way. Overall, our data suggest that DICAM + mononuclear phagocytes play a role in controlling neuroinflammation.

Article activity feed